ArticleCurrent pharmaceutical biotechnology2026
Polygonati Rhizoma Alleviates Vascular Dementia through Regulating Microglial Polarization Transitions Mediated by NF-κB/NLRP3 Pathway.
Article in Current pharmaceutical biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesPolygonati rhizoma (PR) has been used for thousands of years to alleviate dementia. Here, we aimed to elucidate the effect of alleviating vascular dementia (VaD) and underlying mechanism of PR.
methodsIn vivo, rats were treated with two-vessel occlusion (2VO) induces VaD. The anti-VaD effect measured by learning and memory capacity, cerebral pathological structure, and cerebral microglial M1/M2 phenotype biomarkers. Subsequently, screening potential mechanisms of PR for VaD using network pharmacology and molecular docking methods. Moreover, the efficacy of PR-contained serum on LPS-induced inflammation and polarization on BV2 microglia was evaluated with NF-κB/NLRP3 pathway.
resultsIn vivo, PR significantly enhanced learning and memory capacity, suppressed M1 microglia activation and promoted M2 polarization. Through network pharmacology and molecular docking approaches, we screened inflammation as a potential mechanism for PR anti-VaD, with targets involving NF-κB. Meanwhile, PR could regulate the expression of NF-κB/NLRP3 pathway compared with that of LPS-induced BV2 cells. Furthermore, by utilizing PDTC, an NF-κB antagonist, it was found that the effect of PR was similar to that of PDTC.
conclusionPR could hamper inflammation and microglial polarization in 2VO-induced VaD and LPS-induced BV2 cells. Our results showed that PR was a promising Chinese herb to alleviate VaD, and the potential mechanism might be related to NF-κB/NLRP3 signaling pathway.
Indexed as
Identifiers
39936434What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.